OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Experimental & Clinical Cancer Research is 66. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer	393
Correction: circular RNA circATP9A promotes non-small cell Lung cancer progression by interacting with HuR and by promoting extracellular vesicles-mediated macrophage M2 polarization	325
Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway	321
The neuronal protein Neuroligin 1 promotes colorectal cancer progression by modulating the APC/β-catenin pathway	296
Chemotherapy-induced PTEN-L secretion promotes the selection of PTEN-deficient tumor cells	250
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation	248
Regulatory role of lncH19 in RAC1 alternative splicing: implication for RAC1B expression in colorectal cancer	247
Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer	207
CRISPR-Cas9 knockout screening identifies KIAA1429 as an essential gene in Ewing sarcoma	198
Retraction Note: TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells	170
MYSM1 inhibits human colorectal cancer tumorigenesis by activating miR-200 family members/CDH1 and blocking PI3K/AKT signaling	162
Retraction Note: Tripartite motif-containing 14 (TRIM14) promotes epithelial-mesenchymal transition via ZEB2 in glioblastoma cells	149
Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer	141
Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer	138
CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect	135
The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors	133
Ref-1 redox activity alters cancer cell metabolism in pancreatic cancer: exploiting this novel finding as a potential target	132
SEC23A confers ER stress resistance in gastric cancer by forming the ER stress-SEC23A-autophagy negative feedback loop	132
Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy	132
LncRNA MILIP links YBX1 to translational activation of Snai1 and promotes metastasis in clear cell renal cell carcinoma	129
The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression	126
LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2	124
Super-enhancer-associated TMEM44-AS1 aggravated glioma progression by forming a positive feedback loop with Myc	124
PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p	123
The role of TBK1 in cancer pathogenesis and anticancer immunity	120

The RP11-417E7.1/THBS2 signaling pathway promotes colorectal cancer metastasis by activating the Wnt/β-catenin pathway and facilitating exosome-mediated M2 macrophage polarization	119
The RNA-binding protein GRSF1 promotes hepatocarcinogenesis via competitively binding to YY1 mRNA with miR-30e-5p	117
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer	114
CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response	110
Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer	109
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer	107
Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma	105
HIF-1α switches the functionality of TGF-β signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung cancer	103
HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway	102
Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma	100
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma	99
Targeting the HLA-E–NKG2A axis in combination with MS-275 enhances NK cell-based immunotherapy against DMG	95
Fast detection, a precise and sensitive diagnostic agent for breast cancer	89
Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade	89
Targeting homologous recombination deficiency in uterine leiomyosarcoma	88
EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance	84
The importance of being CAFs (in cancer resistance to targeted therapies)	84
Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade	83
Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models	82
Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers	82
Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment	81
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma	81
WNT11/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer	80
Correction: GPR119 agonist enhances gefitinib responsiveness through lactate-mediatedinhibition of autophagy	80
Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy	80
Correction to: Epigenetic mediated zinc finger protein 671 downregulation promotes cell proliferation and tumorigenicity in nasopharyngeal carcinoma by inhibiting cell cycle arrest	79
Correction: Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer	79
Correction: LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond	79
Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth	78
Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop	77
C-Myc-activated long non-coding RNA LINC01050 promotes gastric cancer growth and metastasis by sponging miR-7161-3p to regulate SPZ1 expression	76
Correction: Deliberation concerning the role of M1-type macrophage subset in oral carcinogenesis	75
Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth	74
Gut microbiota-mediated immunomodulation in tumor	72
Plasma-derived extracellular vesicles miR-335–5p as potential diagnostic biomarkers for fusion-positive rhabdomyosarcoma	72
Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance	71
Cellular based immunotherapy for primary liver cancer	70
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis	69
The CD70-CD27 axis in oncology: the new kids on the block	69
Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe	68
Correction to: Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer	67
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy	66
Cellular senescence in cancer: clinical detection and prognostic implications	66
PARD3 drives tumorigenesis through activating Sonic Hedgehog signalling in tumour-initiating cells in liver cancer	66
Kremen2 drives the progression of non-small cell lung cancer by preventing SOCS3-mediated degradation of EGFR	66